Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

F&P Healthcare beats annual profit forecasts

F&P Healthcare beats annual profit forecasts, says earnings will increase further this year

By Tina Morrison

May 29 (BusinessDesk) - Fisher & Paykel Healthcare, the medical device maker, beat its forecast for annual profit and said earnings would rise further in the coming year.

Net profit rose 17 percent to $113.2 million in the year ended March 31, ahead of its forecast range of $105 million to $110 million, the Auckland-based company said in a statement. Revenue increased 8 percent to $672.3 million, ahead of the forecast $660 million.

Fisher & Paykel today forecast profit in the coming year of $125 million to $130 million, on revenue of $750 million.

The company, which competes with Resmed and Respironics, boosted sales of respiratory and acute care products by 9.3 percent to $368.2 million, and sales of obstructive sleep apnea devices by 7.8 percent to $291.1 million. It expanded its gross margin to 61.1 percent, from 58.6 percent the year earlier.

"We have exceeded our earnings guidance provided in November as a result of robust revenue growth in both major product groups, a continuation of gross margin expansion and through operating leverage, and despite a $26.7 million reduction in foreign exchange hedging gains compared to the prior year,” said chief executive Michael Daniell.

Fisher & Paykel exports the vast majority of its products. Excluding the impacts of currency movements, revenue rose 13 percent and operating profit jumped 57 percent, it said.

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

The company will pay a dividend of 8 cents per share on July 10, up from 7 cps the year earlier. It expects to pay out about 70 percent of net profit after tax to maintain its target gearing ratio, compared with a previous aim of more than 60 percent.

Fisher & Paykel, which gets 43 percent of its sales from the US, will assume direct responsibility for its respiratory care products in that market from July 19 after previous distributor CareFusion was taken over by Becton Dickinson. The company has expanded its distribution centre in the US and is doubling the size of its US hospital sales and support team.

An inventory sell down by the current distributors will have a temporary effect on respiratory and acute care revenue growth in the first half of this year, Daniell said.

Still, the increased focus that will be brought to selling the company's products is expected to support an increase in revenue growth over time, he said.

In the past year, Fisher & Paykel increased research and development spending by 20 percent to $65 million. Its updated AIRVO flow generator systems with new breathing tube technology, a new nasal cannula range and portable power supply is the first of a number of new products to be launched over the next 18 months, Daniell said.

Shares in Fisher & Paykel last traded at $6.30 and have edged up 0.8 percent so far this year.

(BusinessDesk)

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
GenPro: General Practices Begin Issuing Clause 14 Notices

GenPro has been copied into a rising number of Clause 14 notices issued since the NZNO lodged its Primary Practice Pay Equity Claim against General Practice employers in December 2023.More

SPADA: Screen Industry Unites For Streaming Platform Regulation & Intellectual Property Protections

In an unprecedented international collaboration, representatives of screen producing organisations from around the world have released a joint statement.More

 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.